

**NEURON SPECIFIC
ENOLASE (NSE), SERUM
(ECLIA)**

ng/mL

15.70-17.00

- Note:** 1. False negative / positive results are observed in patients receiving mouse monoclonal antibodies for diagnosis or therapy
2. NSE values regardless of levels should not be interpreted as absolute evidence for the presence or absence of disease. All values should be correlated with clinical findings and results of other investigations

Clinical Use

- Monitoring disease progression and therapy in patients with tumors particularly Small Cell Lung Carcinoma and Neuroblastoma.
- Response to chemotherapy – there is a temporary rise in NSE level 24-72 hours following first cycle of chemotherapy. This is followed by a rapid fall in serum levels within a week. Non responders to chemotherapy do not show this decrease in levels.
- Monitoring relapse of tumors – during remission 80-96% of the patients have normal NSE levels. Rising values indicate relapse.
- Useful as a single prognostic factor and activity marker during the monitoring of therapy and course of disease in Small Cell Lung Carcinoma (SCLC).

DISEASE	PERCENTAGE POSITIVITY OF NSE
Small Cell Lung Carcinoma (SCLC)	92
Neuroblastoma	62
APUDoma	34
Seminoma	68-73
Non pulmonary malignant disease	22

Increased Levels

- Malignant conditions - Small Cell Lung Carcinoma (SCLC), Seminoma, APUDoma, Neuroblastoma, Brain tumors, Malignant melanoma, Pheochromocytoma
- Non malignant conditions – Benign pulmonary diseases, cerebral diseases like cerebrovascular meningitis, disseminated encephalitis, spinocerebellar degeneration, cerebral ischaemia and infarction, inflammatory brain disease

Dr Lal PathLabs